Pure Global AI
NCT05929612Recruiting

A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma

A Phase II Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma
M.D. Anderson Cancer CenterPhase 2ClinicalTrials.govradiation
Verified
Study focus
Disease/Condition
Lymphoma
Drug/Device/Intervention
Ultra Low Dose 4 Gy Radiation
Study type
Interventional
Intervention type
radiation
Sponsor & location
Primary sponsor
M.D. Anderson Cancer Center
Location
Houston, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Jul 28, 2023
End date
Dec 31, 2027
Enrollment
50 participants
Primary outcome

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Summary

To learn if response-adapted, ultra-low dose radiation therapy can help to control MZL. This
 means participates first receive lower does of radiation therapy and then, based on how the
 disease responds, may receive higher doses after that.

ICD-10 classifications
Hodgkin lymphomaFollicular lymphomaNon-Hodgkin lymphoma, unspecifiedFollicular lymphoma, unspecifiedHodgkin lymphoma, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05929612
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05929612 through Pure Global AI's free database. This Phase 2 trial is sponsored by M.D. Anderson Cancer Center and is currently Recruiting. The study focuses on Lymphoma. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.